top of page



January 2024 Newsletter

August 2023 Newsletter

March 2023 Newsletter

July 2022 Newsletter

January 2022 Newsletter

July 2021 Newsletter

January 2021 Newsletter

July 2020 Newsletter

January 2020 Newsletter
July 2019 Newsletter

January 2019 Newsletter

CMHC Monthly Newsletter:



December 2023:

Newly Generic Oral Diabetes Medications, Saxagliptin and ertugliflozin are now available generic. 

June 2023:

Empagliflozin is now approved in kids with T2DM down to age 10.

The FDA and Novo Nordisk warn of Counterfeit Semaglutide pens:

Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is now available for treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). And for the replacement of endogenous GH in adults with growth hormone deficiency (GHD).

May 2023:

Novel insulin pump recently cleared by FDA

May 2023:

FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular death (CV), hospitalization for heart failure (HF), and urgent HF visit in adults with HF regardless of left ventricular ejection fraction (LVEF) status. Previously it had only been approved for HF patients with reduced ejection fraction (HFrEF).

March 2022: 

FDA approves DEXCOM G7

FDA approves Freestyle Libre 3 

FDA approves Tzield

May 17, 2022: 

FDA approves Mounjaro (tirzepatide)

FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes



ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.


Throughout the year, board members communicate frequently via email and conference calls. 

bottom of page